This early-phase study tested a new vaccine called SPYVLP01 designed to prevent cytomegalovirus (CMV) infection. Researchers gave the vaccine to 120 healthy adults aged 18-50 to check its safety and how well it triggers an immune response. The vaccine was tested with and without …
Phase: PHASE1 • Sponsor: SpyBiotech Limited • Aim: ⭐️ VACCINE ⭐️
Last updated May 04, 2026 16:17 UTC